<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>
<channel>
    	<title>IJPRS/V3/I1/00061 - 12/02/2014</title>

	<item>
		<title>Efficacy and Safety Profile of Siddha Compound Madhumega choornam (MMC) in Type II Diabetic Patients</title>
		
		<description><![CDATA[<h5>Author's Affiliation</h5>
		                                                <p></p>
		                                                <hr/>
                                                    	<h5>Abstract</h5>
		                                                <p><em>Madhumega choornam </em>(MMC) is a well-known polyherbal Siddha formulation. It is in practice for the treatment of Madhumegam (diabetes) for more than four decades. Present study was undertaken to evaluate antidiabetic activity of MMC, containing seven herbs viz., <em>Murraya koenigii, Terminalia chebula, Emblica officinalis, Tinospora cordifolia</em>, <em>Syzygium cumini, Cyperus rotundus </em>and<em> Phyllanthus niruri, </em>in type 2 diabetes individuals of Tamil Nadu, South India. This study is an open, non-comparative, non-randomized, phase IV clinical trial spanning 20 weeks. About 95 subjects of age range between 20-65 years with fasting plasma glucose (FPG) between 126-149mg/dl and two-hour postprandial plasma glucose (PPPG) between 200-299 mg/dl were included in the study. Fasting plasma glucose and postprandial glucose, glycosylated hemoglobin, lipid profile, heamatology, renal and liver function test were performed at baseline and at the end of 20<sup>th</sup> week. A paired t-test was used to assess the statistical significance between baseline and final measurements. Paired t-test revealed that the fasting (p=0.046) and postprandial blood glucose (p&lt;0.001) and HbA1c (p&lt;0.001) showed significant reduction after MMC intervention. The liver, renal functions along with the hematological parameters were well within the normal range. The results suggest MMC to be beneficial for the treatment of type 2 diabetes, further<em> </em>follow-up<em> </em>studies are warranted to confirm the safety aspects of MMC use.</p>
                                                    	<hr/>
                                                        <h5>Keywords</h5>
                                                         <p>Antidiabetic, Siddha medicine, Safety</p>
                                                         
                                                    	                                                    	<hr/>
                                                         <h5>Cite This Article</h5>
                                                         <p>Sadagopan, T., Chandrasekharan, A., Vijayakumar, H., Chidambaram, S., Lakkakula, B. V. K. S. (2014). Efficacy and Safety Profile of Siddha Compound Madhumega choornam (MMC) in Type II Diabetic Patients. <em>International Journal for Pharmaceutical Research Scholars, 3(1),</em> 322-329.</p>                                                         <hr/>
                                                         <p><a class="a2a_button_facebook" href="https://www.addtoany.com/add_to/facebook?linkurl=https%3A%2F%2Fwww.ijprs.com%2Farticle%2Fefficacy-and-safety-profile-of-siddha-compound-madhumega-choornam-mmc-in-type-ii-diabetic-patients%2F&amp;linkname=Efficacy%20and%20Safety%20Profile%20of%20Siddha%20Compound%20Madhumega%20choornam%20%28MMC%29%20in%20Type%20II%20Diabetic%20Patients" title="Facebook" rel="nofollow noopener" target="_blank"></a><a class="a2a_button_twitter" href="https://www.addtoany.com/add_to/twitter?linkurl=https%3A%2F%2Fwww.ijprs.com%2Farticle%2Fefficacy-and-safety-profile-of-siddha-compound-madhumega-choornam-mmc-in-type-ii-diabetic-patients%2F&amp;linkname=Efficacy%20and%20Safety%20Profile%20of%20Siddha%20Compound%20Madhumega%20choornam%20%28MMC%29%20in%20Type%20II%20Diabetic%20Patients" title="Twitter" rel="nofollow noopener" target="_blank"></a><a class="a2a_dd addtoany_share_save addtoany_share" href="https://www.addtoany.com/share#url=https%3A%2F%2Fwww.ijprs.com%2Farticle%2Fefficacy-and-safety-profile-of-siddha-compound-madhumega-choornam-mmc-in-type-ii-diabetic-patients%2F&#038;title=Efficacy%20and%20Safety%20Profile%20of%20Siddha%20Compound%20Madhumega%20choornam%20%28MMC%29%20in%20Type%20II%20Diabetic%20Patients" data-a2a-url="https://www.ijprs.com/article/efficacy-and-safety-profile-of-siddha-compound-madhumega-choornam-mmc-in-type-ii-diabetic-patients/" data-a2a-title="Efficacy and Safety Profile of Siddha Compound Madhumega choornam (MMC) in Type II Diabetic Patients"></a></p>]]>
        </description>
		<link>https://www.ijprs.com/article/efficacy-and-safety-profile-of-siddha-compound-madhumega-choornam-mmc-in-type-ii-diabetic-patients/</link>
		<author>Sadagopan, T., Chandrasekharan, A., Vijayakumar, H., Chidambaram, S., Lakkakula, B. V. K. S.        </author>

		<pdflink>http://www.ijprs.com/wp-content/uploads/2018/09/3-IJPRS-V3-I1-00061.pdf</pdflink>

	</item>
</channel>
</rss>
